Still on the fence with Fluoride?

k15n1 said:

This is almost a religious issue.

Click to expand...

k15n1 said:

From UoToDate, a database used by physicians to keep up with medical research (below). Apparently, it is a rare condition.

......

Halogenoderma Ingestion of halogens such as iodides, bromides, and fluorides can rarely cause cutaneous drug reactions [59].

Iodides (such as those in seaweed, salt, amiodarone, and radiocontrast media) can cause acneiform lesions, typically on the face, as well as vesicular, pustular, hemorrhagic, urticarial, fungating, suppurative, nodular, and ulcerative lesions. Swelling of the parotid and submandibular glands has been previously described as iodine mumps. Iododerma due to the administration of intravenous radiocontrast media commonly is seen as an acute eruption; with oral iodine exposure the onset is insidious [60]. Declining renal function may be a factor in radiocontrast induced iododerma.

Bromides can cause verrucous ulcerating plaques on the lower extremities [59].

Discontinuation of the causative agent is sufficient in most patients, with gradual resolution of lesions expected over four to six weeks [59].

Cytokine therapy Hematopoietic colony stimulating factors are a heterogeneous group of cytokines that induce proliferation and differentiation of bone marrow precursor cells. They are most frequently administered in the setting of neutropenia secondary to chemotherapy (eg, recombinant human granulocyte or granulocyte-macrophage colony-stimulating factor). Serious cutaneous adverse effects of colony stimulating factors are distinctly rare but include neutrophilic dermatoses and necrotizing vasculitis [61]. Upregulation of neutrophil function and secondary release of cytokines may induce these complications.

Both bullous pyoderma gangrenosum and Sweet's syndrome have been associated with hematologic malignancies (particularly acute myeloid leukemia [AML]). It has not been proven that AML cells secrete granulocyte colony-stimulating factor.
Use of UpToDate is subject to the Subscription and License Agreement.
REFERENCES

Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331:1272.
Stern, RS, Shear, NH. Cutaneous reactions to drugs and biological modifiers. In: Cutaneous Medicine and Surgery, vol 1, Arndt, KA, LeBoit, PE, Robinson, JK, Wintroub, BU (Eds), WB Saunders, Philadelphia 1996. p.412.
Yawalkar N. Drug-induced exanthems. Toxicology 2005; 209:131.
Segal AR, Doherty KM, Leggott J, Zlotoff B. Cutaneous reactions to drugs in children. Pediatrics 2007; 120:e1082.
Shear, NH, Knowles, SR, Shapiro, L. Cutaneous reactions to drugs. In: Fitzpatrick's Dermatology in General Medicine, 7th ed, Wolff, K, Goldsmith, LA, Katz, SI, et al (Eds), McGraw Hill, 2008. p. 355.
Calabrese LH, Duna GF. Drug-induced vasculitis. Curr Opin Rheumatol 1996; 8:34.
Calabrese LH, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis. Arthritis Rheum 1990; 33:1108.
Parker CW. Allergic reactions in man. Pharmacol Rev 1982; 34:85.
Mullick FG, McAllister HA Jr, Wagner BM, Fenoglio JJ Jr. Drug related vasculitis. Clinicopathologic correlations in 30 patients. Hum Pathol 1979; 10:313.
Martinez-Taboada VM, Blanco R, Garcia-Fuentes M, Rodriguez-Valverde V. Clinical features and outcome of 95 patients with hypersensitivity vasculitis. Am J Med 1997; 102:186.
Fitzpatrick, TB, Eisen, AZ, Wolff, K, et al (Eds). Dermatology in General Medicine, 4th ed, McGraw-Hill, New York 1993. p.528.
Auquier-Dunant A, Mockenhaupt M, Naldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002; 138:1019.
de Frutos C, de Barrio M, Tornero P, et al. Erythema multiforme from sulfaguanidine. Contact Dermatitis 2002; 46:186.
Forman R, Koren G, Shear NH. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience. Drug Saf 2002; 25:965.
Ziemer M, Wiesend CL, Vetter R, et al. Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2007; 143:711.
Conger LA Jr, Grabski WJ. Dilantin hypersensitivity reaction. Cutis 1996; 57:223.
Bohan KH, Mansuri TF, Wilson NM. Anticonvulsant hypersensitivity syndrome: implications for pharmaceutical care. Pharmacotherapy 2007; 27:1425.
Gogtay NJ, Bavdekar SB, Kshirsagar NA. Anticonvulsant hypersensitivity syndrome: a review. Expert Opin Drug Saf 2005; 4:571.
Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 1996; 15:250.
Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 2007; 48:1223.
Eshki M, Allanore L, Musette P, et al. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol 2009; 145:67.
Ganeva M, Gancheva T, Lazarova R, et al. Carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: report of four cases and brief review. Int J Dermatol 2008; 47:853.
Descamps V, Valance A, Edlinger C, et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2001; 137:301.
Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2007; 156:609.
Namazy JA, Simon RA. Sensitivity to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2002; 89:542.
Husermann P, Harr T, Bircher AJ. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? Contact Dermatitis 2004; 51:297.
Thyssen JP, Maibach HI. Drug-elicited systemic allergic (contact) dermatitis--update and possible pathomechanisms. Contact Dermatitis 2008; 59:195.
Gonzlez E, Gonzlez S. Drug photosensitivity, idiopathic photodermatoses, and sunscreens. J Am Acad Dermatol 1996; 35:871.
Brenner S, Bialy-Golan A, Ruocco V. Drug-induced pemphigus. Clin Dermatol 1998; 16:393.
Stern, RS, Shear, NH. Cutaneous reactions to drugs and biological modifiers. In: Arndt, KA, LeBoit, PE, Robinson, JK, Wintroub, BU (eds). Cutaneous Medicine and Surgery, vol 1, W.B. Saunders, Philadelphia 1996, p.412.
Smith EP, Taylor TB, Meyer LJ, Zone JJ. Antigen identification in drug-induced bullous pemphigoid. J Am Acad Dermatol 1993; 29:879.
Vassileva S. Drug-induced pemphigoid: bullous and cicatricial. Clin Dermatol 1998; 16:379.
Kuechle MK, Stegemeir E, Maynard B, et al. Drug-induced linear IgA bullous dermatosis: report of six cases and review of the literature. J Am Acad Dermatol 1994; 30:187.
Halevy S. Acute generalized exanthematous pustulosis. Curr Opin Allergy Clin Immunol 2009; 9:322.
Roujeau JC, Bioulac-Sage P, Bourseau C, et al. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol 1991; 127:1333.
Momin SB, Del Rosso JQ, Michaels B, Mobini N. Acute generalized exanthematous pustulosis: an enigmatic drug-induced reaction. Cutis 2009; 83:291.
Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005; 209:123.
Horn, TD, Hiatt, KM. Cutaneous toxicities of drugs. In: Lever's Histopathology of the Skin, 9th ed, Elder, DE, Elenitsas, R, Johnson, BL, et al (Eds), Lippincott Williams and Wilkins, Philadelphia 2005. p.323.
Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol 2007; 157:989.
Mashiah J, Brenner S. A systemic reaction to patch testing for the evaluation of acute generalized exanthematous pustulosis. Arch Dermatol 2003; 139:1181.
Guevara-Gutierrez E, Uribe-Jimenez E, Diaz-Canchola M, Tlacuilo-Parra A. Acute generalized exanthematous pustulosis: report of 12 cases and literature review. Int J Dermatol 2009; 48:253.
Lim CS, Lim SL. Acute generalized exanthematous pustulosis associated with asymptomatic Mycoplasma pneumoniae infection. Arch Dermatol 2009; 145:848.
Manzano S, Guggisberg D, Hammann C, Laubscher B. [Acute generalized exanthematous pustulosis: first case associated with a Chlamydia pneumoniae infection]. Arch Pediatr 2006; 13:1230.
Klein N, Hartmann M, Helmbold P, Enk A. [Acute generalized exanthematous pustulosis associated with recurrent urinary tract infections]. Hautarzt 2009; 60:226.
Thompson DF, Skaehill PA. Drug-induced lichen planus. Pharmacotherapy 1994; 14:561.
Asarch A, Gottlieb AB, Lee J, et al. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol 2009; 61:104.
Tosi A, Misciali C, Piraccini BM, et al. Drug-induced hair loss and hair growth. Incidence, management and avoidance. Drug Saf 1994; 10:310.
Gilliam AC, Wood GS. Cutaneous lymphoid hyperplasias. Semin Cutan Med Surg 2000; 19:133.
Crowson AN, Magro CM. Antidepressant therapy. A possible cause of atypical cutaneous lymphoid hyperplasia. Arch Dermatol 1995; 131:925.
Magro CM, Crowson AN. Drug-induced immune dysregulation as a cause of atypical cutaneous lymphoid infiltrates: a hypothesis. Hum Pathol 1996; 27:125.
Cogrel O, Beylot-Barry M, Vergier B, et al. Sodium valproate-induced cutaneous pseudolymphoma followed by recurrence with carbamazepine. Br J Dermatol 2001; 144:1235.
Cohen PR. Acral erythema: a clinical review. Cutis 1993; 51:175.
Hess E. Drug-related lupus. N Engl J Med 1988; 318:1460.
Fritzler MJ. Drugs recently associated with lupus syndromes. Lupus 1994; 3:455.
Bauer KA. Coumarin-induced skin necrosis. Arch Dermatol 1993; 129:766.
Broekmans, AW, Teepe, RG, van der Meer, FJ, et al. Protein C (PC) and coumarin-induced skin necrosis. Thromb Res 1986; 6:137.
Sack U, Kuhn H, Ermann J, et al. Synovial tissue implants from patients with rheumatoid arthritis cause cartilage destruction in knee joints of SCID.bg mice. J Rheumatol 1994; 21:10.
Gupta AK, Knowles SR, Gupta MA, et al. Lithium therapy associated with hidradenitis suppurativa: case report and a review of the dermatologic side effects of lithium. J Am Acad Dermatol 1995; 32:382.
Crowson AN, Brown TJ, Magro CM. Progress in the understanding of the pathology and pathogenesis of cutaneous drug eruptions : implications for management. Am J Clin Dermatol 2003; 4:407.
Chang MW, Miner JE, Moiin A, Hashimoto K. Iododerma after computed tomographic scan with intravenous radiopaque contrast media. J Am Acad Dermatol 1997; 36:1014.
Johnson ML, Grimwood RE. Leukocyte colony-stimulating factors. A review of associated neutrophilic dermatoses and vasculitides. Arch Dermatol 1994; 130:77.

Click to expand...

k15n1 said:

This is almost a religious issue.

Click to expand...

According to the Centers for Disease Control, 32% of American children now have some form of dental fluorosis, with 2 to 4% of children having the moderate to severe stages (CDC 2005).

While proponents of water fluoridation dismiss dental fluorosis as being simply a "cosmetic effect," recent research indicates that the rate of bone fracture among children with fluorosis (even in the mild forms) is higher than the bone fracture rates among children with no fluorosis.

As noted by Dr. Hardy Limeback, Head of Preventive Dentistry at the University of Toronto, "it is illogical to assume that tooth enamel is the only tissue affected by low daily doses of fluoride ingestion."

Click to expand...